Gray and white matter brain chemistry in young children with autism
- PMID: 16818868
- DOI: 10.1001/archpsyc.63.7.786
Gray and white matter brain chemistry in young children with autism
Abstract
Context: The brain pathophysiological abnormalities underlying autism remain unclear. Neuroimaging and histological studies suggest cellular abnormalities early in the course of the disease.
Objective: To measure the in vivo chemical profile of gray and white matter tissues in autism.
Design: Cross-sectional spectroscopic imaging study comparing 3- to 4-year-old children with autism spectrum disorder (ASD) with age-matched comparison groups of children with delayed development (DD) and typical development (TD).
Setting: The University of Washington Diagnostic Imaging Sciences Center, Seattle.
Participants: Forty-five 3- to 4-year-old children with ASD, 12 age-matched children with DD, and 10 age-matched children with TD.
Main outcome measures: Estimates of gray and white matter concentrations for choline-containing compounds (Cho), creatine plus phosphocreatine, N-acetylaspartate (NAA), and myo-inositol (mI). Transverse relaxation times for Cho, creatine plus phosphocreatine, and NAA expressed relative to control subjects with TD were examined to evaluate tissue compactness.
Results: The children with ASD demonstrated decreased gray matter concentrations of Cho (P < .001), creatine plus phosphocreatine (P = .02), NAA (P = .02), and mI (P = .008) compared with children with TD. Gray matter Cho transverse relaxation was also prolonged for the ASD sample compared with the TD group (P = .01). The children with ASD demonstrated significantly decreased levels of Cho (P = .04) and mI (P = .008) and trend-level NAA (P = .09) in gray matter compared with the DD group. For white matter, both children with ASD and children with DD showed a similar pattern of NAA and mI level decreases (for children with ASD vs children with TD: NAA, P = .03; mI, P = .04; for children with DD vs children with TD, NAA, P = .03; mI, P = .07). In several analyses, cerebral volume contributed significantly as a covariate.
Conclusions: Reduced gray matter chemical concentrations and altered Cho transverse relaxation, in a pattern distinct from that in children with DD, suggest decreased cellularity, or density, at this early time point in ASD. Possibly reflecting shared developmental features, white matter results were common to ASD and DD groups. The relationship between cerebral volume and neurochemistry at this early time point may indicate processes related to unit scaling.
Similar articles
-
Atypical developmental patterns of brain chemistry in children with autism spectrum disorder.JAMA Psychiatry. 2013 Sep;70(9):964-74. doi: 10.1001/jamapsychiatry.2013.1388. JAMA Psychiatry. 2013. PMID: 23903694
-
Regional brain chemical alterations in young children with autism spectrum disorder.Neurology. 2003 Jan 14;60(1):100-7. doi: 10.1212/wnl.60.1.100. Neurology. 2003. PMID: 12525726 Clinical Trial.
-
Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.Arch Neurol. 1996 Feb;53(2):167-74. doi: 10.1001/archneur.1996.00550020079018. Arch Neurol. 1996. PMID: 8639067 Free PMC article.
-
Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review.Autism Res. 2013 Apr;6(2):119-33. doi: 10.1002/aur.1273. Epub 2013 Feb 21. Autism Res. 2013. PMID: 23436782 Review.
-
(1)H MR spectroscopy in pediatrics.Eur J Radiol. 2008 Aug;67(2):240-249. doi: 10.1016/j.ejrad.2008.02.035. Epub 2008 Apr 21. Eur J Radiol. 2008. PMID: 18423936 Review.
Cited by
-
Catecholaminergic and cholinergic neuromodulation in autism spectrum disorder: A comparison to attention-deficit hyperactivity disorder.Front Neurosci. 2023 Jan 6;16:1078586. doi: 10.3389/fnins.2022.1078586. eCollection 2022. Front Neurosci. 2023. PMID: 36685234 Free PMC article. Review.
-
Proton magnetic resonance spectroscopy and MRI reveal no evidence for brain mitochondrial dysfunction in children with autism spectrum disorder.J Autism Dev Disord. 2012 Jan;42(1):105-15. doi: 10.1007/s10803-011-1216-y. J Autism Dev Disord. 2012. PMID: 21404085
-
Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism.Neuropsychopharmacology. 2014 Mar;39(4):831-40. doi: 10.1038/npp.2013.274. Epub 2013 Oct 7. Neuropsychopharmacology. 2014. PMID: 24096295 Free PMC article.
-
Neurometabolite levels in the brains of patients with autism spectrum disorders: A meta-analysis of proton magnetic resonance spectroscopy studies (N = 1501).Mol Psychiatry. 2023 Jul;28(7):3092-3103. doi: 10.1038/s41380-023-02079-y. Epub 2023 Apr 28. Mol Psychiatry. 2023. PMID: 37117459
-
N-acetyl aspartate in autism spectrum disorders: regional effects and relationship to fMRI activation.Brain Res. 2007 Aug 8;1162:85-97. doi: 10.1016/j.brainres.2007.04.081. Epub 2007 May 21. Brain Res. 2007. PMID: 17612510 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources